Table 1. Functional catalytic modes of PLP-enzymes according to the position of net reaction
The evolution on the field of biotechnology and proteomics create a novel therapeutic field (Enzymo-therapy) for treatment of various types of disease, particularly in the last fifty years. Exploitation of enzymes as anticancer, anti-cardiovascular, anticoagulants, antimicrobials and antioxidants (Vellard, 2003) was absolutely approved by Food and Drug Administration (FDA). Practically, almost of tumor cells were reported to be auxotrophs for L-methionine, glutamine, asparagine and arginine, due to the absence of intrinsic enzymatic systems synthesizing these amino acids, thus it depends for their growth and proliferation on the exogenous supply of these amino acids, that usually from diets (Hoffman and Erbe, 1976, Mecham et al., 1983, Pasut et al., 2007, El-Sayed, 2010). Consequently, L-methioninase, L-glutaminase, L-asparaginase and arginine deiminase were frequently used as common anticancer agents by sequestering their corresponding amino acids from the blood plasma (Hoffman, 1985, Klimberg and McClellan, 1996, Agrawal et al., 2003, Cheng et al., 2005).
Additionally, hyperaccumulation of certain metabolic intermediates as homocysteine and cystathionine usually associated with various cardiovascular diseases and complex disorders (Zou and Banerjee, 2005, Wang and Hegele, 2003). Cystathionine β-synthase and cystathionine γ-lyase are potential for sequestering homocysteine and cystathionine via transsulfuration metabolic pathways for production of glutathione and other antioxidants, so, these enzymes were described as anti-cardiovascular agents (Stipanuk, 2004, Zhu et al., 2008).
Unlike traditional approaches, Enzymo-therapy seems to be the promising therapeutic technology for their great specificity and affinity towards a clue substrate on specific metabolic pathway. However, the structural and conformational complexity of these enzymes makes it more vulnerable to extrinsic parameters, modulators, immunogenicity and proteolysis (Tan et al., 1996, Sun et al., 2003, Pasut et al., 2007). In addition, purification and formulation of these therapeutic enzymes, due to the economic expenses may add further complications.
Therefore, the various approaches for stabilization of these enzymes in situ and decreasing their immunogenicity were the objective of this context. The structural and catalytic identity of pyridoxal phosphate enzymes, molecular aspects to enhance their therapeutic potentiality, in addition to our prospectives will be exploited.
2. Pyridoxal 5'-phosphate dependent enzymes: classification and catalytic identities
Pyridoxal 5'-Phosphate (PLP) dependent enzymes, a group of versatile enzymes including about 145 distinct enzyme, 4% of the total cellular enzymatic activities (www.brenda.com) (Thornton et al., 2000, Percudani and Peracchi, 2003) which mainly uses PLP as covalent co-enzyme. PLP is an active phosphorylated derivative of vitamin B6 (pyridoxine) (Heyl et al., 1951). According to the international biochemical, molecular classification of enzymes (Enzyme Commission) (www.chem.qmul.ac.uk/iubmb), PLP-dependent enzymes were distributed in to five groups; 1- Oxido-reductase (EC 1; one enzyme), 2-Transferase (EC 2; eighty enzymes), 3- Hydrolase (EC 3; two enzymes), 4-Lyase (EC 4; Forty nine enzyme), and 5-Isomerase (EC 5; Thirteen enzyme) as totally 145 enzyme (Grishin et al., 1995, Percudani and Peracchi, 2003) as shown in Fig.1.
Practically, all the PLP-dependent-enzymes are mainly involved in amino acids transformation as decarboxylation, transamination, racemization, β, γ-elimination and β, γ-substitution (Percudani and Peracchi, 2003). The multiple functional catalytic modes of PLP-enzymes according to the position of net reaction were summarized in Table 1. PLP coenzyme has a pivotal role in catalysis of various enzymatic reactions. Pyridoxal phosphate can be synthesized de novo from preexisting precursor in bacteria (Brewke and Leistner, 2001), fungi (Bean et al., 2001, Ehrenshaft and Daub, 2001) and plants (Galperin and Koonin, 1997) from erythrose 4-phosphate, pyruvate and D-glyceraldhyde 3-phosphate. However, in human PLP cannot be synthesized de novo, it must be supplemented from the diet as pyridoxine, pyridoxamine and/or pyridoxal. PLP can be formed from pyridoxal via phosphorylation by action of kinase (PdxK; EC. 188.8.131.52), from oxidation of pyridoxamine/ pyridoxine by oxidase (EC. 184.108.40.206) (Choi et al., 1983, Bahn et al., 2002). Structurally, aldehyde group of PLP are bound covalently as internal aldimine (Schiff base)/ imine linkage to the Ɛ-amino group of lysine residues, close to
The role of PLP, during catalysis, is to reduce the energy for conversion of amino acids substrates to a zwitterionic carbonion (Richard and Amyes, 2004), substantially the apoenzyme catalyze the cleavage of substrate target bond yielding the product as reviewed by Richard et al. (2011). Regarding to the native internal aldimine of PLP-enzyme, the catalytic process started with formation of external aldimine linkage of amino group of substrate and pyridoxal phosphate coenzyme forming coenzyme-substrate Schiff base, replacing the Ɛ-amino group of lysine-enzyme (Schirch et al., 1993).This external aldimine of Co-enzyme-substrate Schiff base is the common intermediate for all PLP-dependent enzymes. Interestingly, pyridoxal phosphate without apo-enzyme, can slowly mediate many of reactions while the enzyme can ensure the substrate specificity and catalysis (Toney, 2005, Lopez et al., 2010), that justifies the lack of apoenzyme activity, with potentiality to recover its catalytic state upon supplementation by external PLP (El-Sayed, 2011). Since the formation of external aldimine, the pyridoxal phosphate is bounded tightly to the apoenzyme via nine hydrogen bonds (Johnson et al., 1990, Palm et al., 1990). The PLP extremely withdraw electrons, stabilizing the negative charge at α-carbon (carbanion) of the substrate as transition state that commonly referred as Quinonoid intermediates (Metha and Christen, 2000, Hult and Berglund, 2007). The catalytic promiscuity of PLP-dependent enzymes mainly depends on the mechanistic consequence of quinonoid intermediates (Alexander et al., 1994, Toney, 2005) as shown in Fig. (3).
Depending of crystallographic structures and topological studies, PLP-dependent enzymes were categorized in to five distinct folds (I-V) (Alexander et al., 1994, John, 1995, Jansonius, 1998) as illustrated in Table 2. The five independent fold types of PLP-enzymes were: Fold type I; Aspartate Aminotransferase (AAT) family; the most functionally diverse type containing α and γ-families of PLP-enzymes in which the internal aldimine was formed at lysine of
|Reaction site||Reaction type||Mechanism of Reaction||Example of|
|No.||Fold Type I||No.|
|1||Glycine dehydrogenase||50||Tyrosine decarboxylase|
|2||Glycine hydroxymethyltransferase||51||Glutamate decarboxylase b|
|3||Threonine aldolase||52||Histidine decarboxylase b|
|4||Trptophanase||53||Ornithine decarboxylase 1|
|5||Tyrosine phenol lyase||54||Arginine decarboxylase 1|
|6||Selenocysteine lyase||55||Lysine decarboxylase|
|10||Amino ketobutyrate CoA ligase||Fold Type II|
|11||Aminolevulinate Synthase||1||Aminocyclopropane-carboxyl deaminase|
|12||Amino oxononanoate synthase||2||Tryptophan synthase ?|
|13||Serine palmitoyltransferase||3||Cystathionine ?-synthase|
|15||Isopenicillin ||5||D-Serine dehydratase|
|16||Cysteine desulfurase||6||L-serine dehydratase|
|17||Splicing protein SPL1||7||Threonine dehydratase|
|18||Cystathionine ?-Synthase||8||Threonine synthase 1|
|20||Methionine ?-Lyase||10||Threonine synthase 2|
|21||Cystathionine ?-Lyase||11||D-Alanine aminotransferase|
|22||Cystathionine ?-Lyase||12||Amino deoxychorismate lyase|
|23||Aspartate aminotransferase a||13||Branched amino acid aminotransferase|
|24||Aromatic amino acid aminotransferase|
|26||Alanine aminotransferase||Fold Type III|
|27||1||Ornithine decarboxylase 2|
|28||Phenylpuruvate aminotransferase||2||Diaminopimelate decarboxylase|
|29||Aminocyclopropane carboxylate synthase||3||Arginine decarboxylase|
|30||Rhizopine regulatory protein||alanine racemase|
|31||Aspartate aminotransferase b|
|32||Aspartate aminotransferase c|
|33||Histidinol phosphate aminotransferase||Fold Type IV|
|34||cobC gene product||1||D-amino acid aminotransferase|
|35||Valine-Pyruvate aminotransferase||2||branched chain amino acid amino transferase|
|36||Acetylornithine aminotransferase||3||4-amino-4-deoxychorismate lyase|
|39||Alanine glyoxylate aminotransferase|
|40||Dialkylglycine decarboxylase||Fold type V|
|41||Alanine pyruvate aminotransferase||1||Glycogen phosphorylase|
|42||Aminooxononanoate aminotransferase||2||Maltodextrin phosphorylase|
|43||DNTP hexose aminotransferase|
|44||Glutamate semialdehyde aminomutase|
|48||Glutamate decarboxylase a|
|49||Histidine decarboxylase a|
No hydrogen bonds between pyridine nitrogen and apoenzyme (Percudani and Percacchi, 2003). The systematic and catalytic promiscuity of the five fold types PLP-dependent enzymes as adopted by Metha and Christen (2000) and Percudani and Peracchi (2003), were illustrated in Table 2.
Regarding to our previous work (Khalaf and El-Sayed, 2009, El-Sayed, 2009, 2010, 2011a, b), the subsequent section was focused on the metabolic interactions of sulfur containing amino acid by PLP-dependent enzymes of Aspartate Aminotransferase Family.
3. Metabolic interactions of sulfur-containing amino acids by PLP-dependent enzymes: Biochemical identity of normal and tumor cells
Sulfur-containing amino acids are pivotal compounds for almost of metabolic cellular process. In contrary to humans, plants and microorganisms can synthesize their sulfur containing amino acids from the inorganic precursor as sulfate, sulfite and sulfide via reduction or activation (Beinert, 2000, Kessler, 2006). In humans, methionine and cysteine were described as conditional essential amino acids for normal various biological aspects (Baylin et al., 1998, Davis and Uthus, 2004). The prominent sulfur containing amino acids on living cell are cysteine and methionine, that crucially incorporated on the synthesis of Co-enzyme, vitamins, epigenetic DNA modulators, DNA stabilizers and antioxidants (El-Sayed, 2010and Cellarier et al., 2003). Additionally, cysteine is the essential source for H2S biogenesis that critically acts as neuro-modulators, cardio-protector, relaxing muscle regulators, and vasodiolator for vascular system (Wang, 2002, Kimura, 2010, Predmore and Lefer, 2010and Gadalla and Snyder, 2010). The general metabolic interactions of sulfur containing amino acids and their derivative by PLP-enzymes were illustrated in Fig. (3). Methionine can be metabolized via different ways that collectively regulated by PLP-dependent enzymes as methionine γ-lyase, cystathionine β, γ-synthases and cystathionine β, γ-lyases. In plants and microbes, methionine can be undergoes oxidative deamination/ demethiolation forming methanethiol, α-ketobutyrate and ammonia (Tanaka et al., 1977) via the action of L-methioninase. L-Methioninase was frequently reported as a substrate induced extracellular enzyme for various microbial cultures (Tanaka et al., 1977, Soda et al., 1983; Nikulin et al., 2008, Khalaf and El-Sayed, 2009), while it is absent in mammalian cells (Cooper, 1983). Biochemically, methionine was activated by methionine adenosyltransferase forming
4. Transmethylation pathway and methionine synthesis
Physiologically, tumors are genetically abnormal cells with uncontrolled rapidly growth and proliferation, for mutation on some genes encoding amino acids metabolizing enzymes, comparing to the corresponding normal cells (Hoffman, 1985). Elevated requirements of methionine are the common biochemical criteria by tumor cells comparing to corresponding normal ones, to fulfill their high protein synthesis and regulation of DNA expression (Stern et al., 1984, Swisher et al., 2009). Practically, hypermethylation of DNA is usually correlates with transcriptional silencing of many of tumor suppressor genes, P53 genes, thus disrupting DNA repairing systems and cell signaling modulators (Jones and Baylin, 2002, Santini et al., 2001) as reviewed by El-Sayed (2010). Also, methylation of tumor DNA change the identity of CpG islands, thus altering the expression of DNA repairing and apoptosis controlling genes (Sun et al., 1997, Matsukura et al, 2003) and changing of CpG islands (Swisher et al., 2009). On other hand, suppression of methionine synthase genes are a reliable cellular criteria in various cells as bladder, breast, kidney, lung and hematological tumors (Mecham et al., 1983, Hoffman, 1985, Kreis and Goodenow, 1978), thus it described as methionine dependent cells. In contrast, the normal cells have an active methionine synthase with the ability to form methionine from homocysteine in the presence of methyl tetrahydro folate and betaine as methyl group donors (Kenyon et al., 2002). Consequently, the tumor cells have no ability to grow on homocysteine, comparing to the normal growth of healthy cells. The different argumentations for methionine dependency of tumor cells and biochemical identity of L-methioninase as therapeutic agent were comprehensively interpreted by our previous studies (El-Sayed, 2010).
5. Polyamines synthesis
6. Transsulfuration pathway
Transsulfuration is the main metabolic pathway for transformation of homocysteine to glutathione, and trypanothione (Cellarier et al., 2003), involving two pyridoxal phosphate dependent enzymes, cystathionine β-synthase and γ-lyase (Fig. 3). By cystathionine β-synthase, homocysteine condensates with serine moiety forming cystathionine, that subsequently oxidized to cysteine, α-ketobutyrate and ammonia by cystathionine γ-lyase (Zou and Baerjee, 2005). Biochemically, transsulfuration pathway contributes in maintaining the cellular balance of cysteine-homocysteine pool that participates in about 50% of total antioxidant formation (Zhu et al., 2008). Practically, inactivation of cystathionine β-synthase causes hyperaccumulation of homocysteine that is a visual risk of cardiovascular diseases, damage to vascular endothelia (De Bree et al., 2002, Wald et al., 2002) and Alzheimer's disease (Morris, 2003). Moreover, the deficiency of cystathionine γ-lyase results in accumulation of cystathionine, known as Cystathioninuria that usually accompanied with diabetes, Down's syndrome, neuroblastoma (Wang and Hegele, 2003, Zhu et al., 2008). Glutathione was synthesized by γ-glutamylation (El-Sayed et al., 2010) of cysteine by γ-glutamyl cysteine synthetase, then complexation with glycine forming glutathione by glutathione synthetase (Cellarier et al., 2003) as reviewed by El-Sayed (2010). Trypanothione as dimmer of glutathione molecules joined by sperimidine linker, as powerful antioxidants against stress (Tover et al., 2003).
7. Rationality of PLP dependent enzymes as antitumor and anti-cardiovascular agents
The absolute dependence of tumor cells on the exogenous supply of plasma L-methionine, not homocysteine, due to their lacks to active methionine synthase is the biochemical target for many therapeutic strategies (Cellarier et al., 2003). Unlike the inactivity of methionine synthase in tumor cells, this enzyme was very active in normal cells ensuring their ability for synthesizing required methionine from homocysteine (Anderson, 1998). The argumentation of biochemical dependence of tumors on methionine synthase or their coenzymes for various cell lines corresponding to the normal cells was comprehensively documented (Liteplo et al., 1991; Fiskerstrand et al., 1994, El-Sayed, 2010). Several approaches were designed for triggering the methionine dependency of tumor cells, for example, starvation of the tumor cells from methionine using methionine-free diets that displays a reliable efficacy against various types of tumor cells (Goseki et al. 1992). However, this strategy is practically inefficient for many technical, therapeutical and economical considerations (Hoffman, 1985, Tan et al., 1996, Hoshiya et al., 1997). Consequently, application of L-methioninase for removal of plasma L-methionine is the potent justifiable strategy towards various methionine dependent tumor cells (Anderson, 1998and Kokkinakis, 2006). Methionine depletions cause arresting of tumor cell growth on the late of S-G2 phase undergoing eventually apoptosis (Guo et al., 1993, Nagahama et al., 1998). Biochemically, nutrients with depleted or enriched specific amino acid affect on the growth of normal/tumor cells, according to Harper's concept of amino acid balance. Malnutrition of patient is closely associated with severe amino acid metabolic disorders, uncorrectable nitrogen balance with low activity of immune system (Nitenberg and Raynard, 2000). Interestingly, methionine/ valine depleted, tyrosine lowered and arginine enriched was the most rationalized form for inhibition of tumor growth (Chen et al., 2001, He et al., 2003). L-Methioninase was extensively tested a potent anti-proliferative enzyme towards Lewis lung (Yoshioka et al., 1998), human colon (Tan et al., 1998), glioblastoma (Kokkinakis et al., 2001), neuroblastoma (Hu and Cheung, 2009) as reviewed by Sato and Nozaki (2009) and El-Sayed (2010). Recently, Parenteral nutrition is a common co-supportive strategy for various aspects of tumor therapy (Buchman et al., 2006).
L-Methioninase was purified and characterized from different bacterial isolates (Hoffman and Erbe, 1976; Tanaka et al., 1977, Soda et al., 1983, Nikulin et al., 2008), particularly,
8. Different approaches to increase the therapeutic potentiality of l-methioninase
8.1. PEGylation of L-methioninase
Immobilization of the therapeutic enzymes on polyethylene glycol (PEG), PEGylation, is one of the most successful strategies that originated in 1970 (Abuchowski et al., 1977). PEGylation of albumin and catalase was the milestone for the development and globalization of this technique, as efficient method for modification of the structural and immunogenic identities of proteins (Abuchowski et al., 1977). Polyethylene glycol is a neutral, water soluble, hydrophilic polyether with less immunogenicity that ensure various pharmacological properties as increasing half-life time, reducing the kidney clearance, protecting protein from proteolysis by via steric hindrance, reduce the immunogenicity of protein, increasing the solubility of target therapeutic agent (Reddy, 2000, Veronese and Pasut, 2005, Fee and Van Alsteine, 2004, Pasut and Veronese, 2009). The therapeutic behavior of PEGylated-enzyme was illustrated (Fig. 4). PEGylated-enzyme have a reduced kidney excretion, with more plasma half-life time for the increasing of its molecular size (hydrodynamic radii), masking the sensitive amino to chemical modification, shielding the critical surface active sites from proteolysis, antibodies recognition and/or interaction with inhibitors (Harris, 1991; Zalipsky, 1995; Harris et al., 2001; Veronese and Harris, 2002), comparing to free enzyme. Also, PEGylation reduce the protein opsonization and adhesion to liposomes, microparticles (Fee and Van Alstine, 2004). Currently, PEGylation become a well developed technique for formulations of biopharmaceuticals for improving their solubility, bioavailability and decreasing their immunogenic properties as approved by FDA organization (Pasut et al., 2007). PEGylated forms of therapeutic enzymes as
9. Combination between L-methioninase and chemotherapeutic agents
Synergism between L-methioninase and chemotherapeutic agents present a new strategy against various types of tumors (Yoshioka et al., 1998). Biochemically, starvation of the tumor cells to L-methionine, by action of L-methioninase or L-methionine depleted diets usually make the tumor cells more vulnerable to any biochemical modulator as reviewed by El-Sayed (2010). Methionine starvation and simultaneous phase-specific chemotherapeutic agent is an overall concept for all therapeutic strategies. 5-Fluorouracil, common biochemical modulator, an analogue to thiamine, that competitively bind to thymidylate synthetase, causing prompted suppression to DNA synthesis of tumor cells (Poirson-Bichat et al., 1997). The sensitivity of Lewis lung carcinoma to L-methioninase was increased by about 4.5 fold by addition of 5-fluorouracil (Hoshiya et al., 1997, Tan et al., 1998, Yoshioka et al., 1998). Similarly, doxorubicin as intercalating agent blocks the cell cycle, greatly improves the activity of L-methioninase against human lung carcinoma H460 (Gupta et al., 2003). Ethionine, as methionine analogue, in combination with methionine starved diets display a potent activity against human colon and lung tumors, that attributed to inhibition of methyltransferase leading to DNA, RNA, protein hypomethylation (Razin and Riggs, 1980 and Poirson-Bichat et al., 2000). Also, methionine free diets potentiality against human prostate and glioma was strongly augmented by supplementation of ethionine that attributed to reduction of ATP pool and glutathione synthesis (Guo et al., 1996, Poirson-Bichat et al., 1997). Also, methionine deprivation induce the hypomethylation reactions that lowers the glutathione and alters folate metabolism causing selective arresting to the cell cycle in the late of S/G2 phase, strongly modulate the efficiency of Cisplatin against human breast carcinoma (Hoshiya et al., 1996). However, continuous starvation of human serum to methionine may exert hazardous implications to liver (Kokkinakis, 2006). Biochemically, combination of methioninase with various therapeutic agents, for methionine starvation, as doxorubicin (Stern et al., 1984), 5-fluoruracil, mitomycin C (Goseki et al., 1992), nitrosoureas (Kokkinakis et al., 2001) and BCNU (Kokkinakis et al. 1997), display a new approach for treatment of methionine dependent tumor cells.
10. L-Methioninase gene therapy and selenomethionine as prodrugs
Introduction of the L-methioninase encoding genes to tumor cells with regulating their expression one of the recent challenges for treating of tumor cells as reviewed by El-Sayed (2010). Transduction of bacterial L-methioninase gene via developed adenoviral vector, with exogenous L-methioninase, display a powerful activity towards human ovarian cancer cells (Miki et al., 2000a). The potentiality of gene therapy for methionine dependent tumors based on deprivation of the tumor cells from the intrinsic L-methionine, so this technique significantly intensified by combination with external L-methioninase, to remove the serum L-methionine. A plausible anti-proliferative activity towards human lung cancer by transduction of
Currently, in a revolution of biotechnology in the fight against cancer, directing of the enzyme via antibodies to the target tumor cells for removal of extracellular methionine in addition to transduced enzyme gene and selenomethionine as prodrug is the promising strategy against various types of tumors (Napier et al., 2000, Zhao et al., 2006). This novel approach referred as Antibody Directed Enzyme Prodrug Therapy (ADEPT) that is reliable strategy to avoid the systemic clinical and therapeutical limitations of the traditional approaches (Sharma et al., 2005). However, several trials for construction of enzyme antibodies models (Bagshawe, 1987, Stener and Springer, 2001, Bagshawe et al., 2004) were experimented. However, the design of enzyme-antibody without interactions on the enzyme catalytic sites and specific to receptors on the surface of tumor cells is main challenge by biotechnologists, for approving this strategy. After transduction of L-methioninase gene to the target tumor cells, the enzyme-antibody was introduced to the human plasma followed by injection of selenomethionine as planned by several trials as reviewed by El-Sayed (2010).
11. Exploitation of L-methioninase as a target for antimicrobial drugs
Uniqueness distribution of L-methioninase as intracellular enzyme among all microbial pathogens, but not humans makes this enzyme is a novel target for antibacterial, antifungal and anti-protozoal therapies (Ali and Nozaki, 2007, Sato and Nozaki, 2009). Trifluoromethionine (TFM), a fluorinated methionine that undergoes β, γ-elimination forming trifluoro-methanethiol (CF3SH) that converted to carbonothionic difluoride which subsequently interacted with primary amino groups of the enzymes lysine moieties, causing cellular toxicities (Alston and Bright, 1983, Sato et al., 2008). TFM was reported as a potent antibacterial agent towards the growth of
12. Pyridoxal phosphate-dependent enzymes deficiency and cardiovascular diseases
Biochemically, transsulfuration and reverse-transsulfuration pathways are the pivotal mechanisms for proper accumulation of homocysteine and cystathionine. As shown in Fig. (3), these pathways are controlled by four PLP-dependent enzymes namely; cystathionine β, γ-synthases and cystathionine γ, β-lyases. Inactivation of transsulfuration enzymes as cystathionine β-synthase causes hyperaccumulation of homocysteine (homocysteinuria) that is a visual risk of cardiovascular diseases, damage to vascular endothelia, increases to the risk of abnormal blood clots and skeletal abnormalities (De Bree et al., 2002; Wald et al., 2002) and Alzheimer's disease (Morris, 2003). Also, homocysteinuria usually associated with intellectual disability, seizures and megaloblastic anemia (Mudd et al., 1985). Practically, it commonly reported as genetic or metabolic disorders that affect on the metabolism of protein, generally one to 200,000 babies are born with genetic disorders. Homocysteinuria is a biochemically disorder due to the deficiency of cystathionine β-synthase, owing to the genetically inborn error of the transsulfuration pathway that increases the homocysteine and methionine, with crucial decreasing to the cysteine pool (Mudd et al., 1985). The major clinical implication of homocysteinuria includes mental retardation, dislocation of the optic lenses, skeletal abnormalities (Schuh et al., 1984). Dietary therapy relying of deprivation of methionine and supplementation of cysteine display a reliable positive result in delaying the clinical manifestations (Pullon, 1980). However, supplementation of cystathionine β-synthase was the potent relevant therapy for dramatically conversion of homocysteine to cystathionine (Zhu et al., 2008). Since cystathionine β-synthase is a PLP-dependent enzyme and the rapid dissociation of PLP as coenzyme from the apoenzyme is a common structural and catalytic criteria (El-Sayed, 2010, 2011), external supplementation of pyridoxal phosphate, vitamin B6 gave a plausible results for decreasing the amount of homocysteine, assuming the reassociation of apo-cystathionine β-synthase forming the holo-enzyme (Barber and Spaeth, 1967). Moreover, the deficiency of cystathionine γ-lyase results in accumulation of cystathionine (Cystathioninuria) that usually accompanied with diabetes, Down's syndrome, neuroblastoma (Wang and Hegele, 2003) as reviewed by Zhu et al. (2008).
13. Industrial application of l-methioninase: methanethiol production
Methanethiol has enormous biotechnological applications such as key gradient in gas odorants, jet fuel additives and coke formation in steel mill furnaces (Welirnan 1966). Recently, it is used for preparation of modified gold biosensors, manufacturing of plastics and pesticides (Jin et al. 2005, Nakamura et al. 2006). Also, it is the precursor for dimethyltrisulfide,
Chemically, methanethiol can be synthesized by reaction of methanol with hydrogen sulfide (Scott et al., 1955). The reaction was preceded at 380°C (716°F) in the presence of K2MoSO4/SiO2 as catalyst and 2MPa. By chemical methods usually methanethiol accompanied with formaldehyde, requiring more steps for purification, especially with higher solubility of methanethiol in water (Yang et al., 1998). Commercially, the price of methanethiol salt is about eighteen fold higher than L-methionine, also one gram of sodium methanethiolate is 3.6 folds more than one liter of methanol (Sigma-Aldrich Co 2010).
Consequently, the enzymatic method, using L-methioninase seems to be a plausible process for large scale production of methanethiol from the technical and economical point of views. For the high expense of enzyme purification from the microbial cultures, immobilization is a promising technique for enzyme stabilization and continuous production of methanethiol (El-Sayed and Shindia, 2011). Among the tested methods, polyacrylamide (42.2%), Ca-alginate (40.9%) and chitin (40.8%) displaying the highest
14. Prospectives for improving the therapeutic potentiality of PLP-dependent enzymes
Regarding to publications describing the structural and catalytic identities of PLP-dependent enzymes and their wide therapeutic and pharmaceutical applications, the immunogenicity and relative instability were the common limitations from pharmacokinetic point of view. Actually, all of these enzymes that receive considerable attention as therapeutic agent were of bacterial sources as reviewed by El-Sayed (2010). However, the crystallographic and biochemical studies for various therapeutic enzymes reveal a reliable distinction on the enzyme conformational structural of surface amino acids and immunogenic sites, from prokaryotes to eukaryotes (Kusakabe et al., 1979). Unlike the extensive studies of bacterial PLP-dependent enzymes, no more publications for biochemical characterization and crystal structures of these enzymes from eukaryotes, in spite of their distinct structural identity from eukaryotes as revealed from amino acid constitution (El-Sayed, 2010). Thus, further biochemical and crystallographic studies to elucidate the catalytic identity and tertiary structure of eukaryotic PLP-enzymes for the maximum therapeutic exploitation of these enzymes need to be resolved. The plausible re-association of PLP coenzyme with the apo-L-methioninase with full activity, comparing to lower to inability to re-association of the corresponding enzymes from prokaryotes, is an obscure, and their authorization with greatly participates in explanation of their catalytic and immunogenic identities. In addition, immobilization and co-immobilization studies of these enzymes will significantly maximize their biotechnological and therapeutical applications. Regarding to gene therapy, PEGylation and directing of these enzymes to specific tumors via targeting by modified antibodies or nao-particles is the main challenge for our ongoing research.
Abuchowski A. Van E. S. T. Palczuk N. C. Davis F. F. 1977Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252 3578 3581.
Abuchowski A. Van E. S. T. Palczuk N. R. Mc Coy J. R. Davis F. F. 1979Treatment of L5178Y tumor-bearing BDF1 mice with a non-immunogenic L-glutaminase-L-asparaginase. Cancer Treat. Rep. 63 1127 1132.
Agrawal N. R. Bukowski R. M. Rybicki L. A. Kurtzberg J. Cohen L. J. Hussein M. A. 2003A phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myloma. Cancer 98 94 99
Alexander F. W. Sandmeier E. Mehta P. K. Christen P. 1994Evolutionary relationships among pyridoxal-5-phosphate-dependent enzymes. Regio-specific alpha, beta and gamma families. Eur. J. Biochem. 219 953 960.
Ali V. Nozaki T. 2007Current Therapeutics, Their problems, and sulfur-containing amino acid metabolism as a novel target against infections by Amitochondriate Protozoan parasites. Clinical Microbiology Rev. 20 164 187.
Alston T.A. and Bright H.J. 1983Conversion of trifluoromethionine to a cross-linking agent by gamma-cystathionine. Biochem. Pharmacol., 32 947 950.
Amarita F. Yvon M. Nardi M. Chambellon E. Delettre J. Bonnarme P. 2004Identification and functional analysis of the gene encoding methionine-γ-lyase in
Anderson ME 1998Glutathione: an overview of biosynthesis and modulation. Chem. Biol. Interact 112 1 14.
Bagshawe K.D. 1987Antibody directed enzyme revive anticancer prodrug concept. Br. J. cancer, 56 531 532.
Bagshawe K. D. Sharma S. K. Begent R. H. J. 2004Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert. Opinion Biol. Ther. 4 1777 1789.
Bahn J. H. Kwon O. S. Joo H. M. Jang S. H. Park J. Hwang I. K. Kang T. C. Won M. H. Kwon H. Y. Kwok F. Kim H. B. Cho S. W. Choi S. Y. 2002Production of monoclonal antibodies and immuno histochemical studies of brain pyridoxine-5-phosphate oxidase. Brain Res. 925 159 168.
Balcao V. M. Mateo C. Fernandez-Lafuente R. Malcata F. X. Guisan J. M. 2001Co-immobilization of L-asparaginase and glutamate dehydrogenase onto highly activated supports. Enz. Microbial. Technol. 28 696 704.
Barber G.W. and Spaeth G.L. 1967Pyridoxine therapy in homocysteinuria. Lancet 1: 337
Baylin S. B. Herman J. G. Graff J. R. Vertino P. M. Issa J. P. 1998Alteration in DA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72 141 196.
Bayol A. Capdevielle J. Malazzi P. Buzy A. Bonnet M. C. Collocʼh N. Mornon J. P. Layaux D. Ferrara P. 2002Modification of a reactive cysteine explains differences between rasburicase and uricozyme, a natural
Bean L. E. Dvorachek W. H. Braun E. L. Erret A. Saenz G. S. Giles M. D. Erner-Washburne M. Nelson M. A. Nativg D. O. 2001Analysis of the
Beinert H. 2000Iron-sulfur proteins: ancient structures, still full of surprises. J. Biol. Inorg. Chem. 5 2 15.
Bertoldi M. Cellini B. Clausen T. Voltattorni C. B. 2002Spectroscopic and kinetic analyses reveal the pyridoxal 5-phosphate binding mode and the catalytic features of
Brewke C. Leistner E. 2001Biosynthesis of vitamin B6 and structurally related derivatives. Vitam. Horm. 61 121 155.
Buchman A. L. Lyaer K. Fryer J. 2006Parenteral nutrition-associated liver disease and the role for isolated intestine and intestine/liver transplantation. Hepatology 43 9 19.
Burkhard P. Rao G. S. Hohenester E. Schnackerz K. Cook P. F. Jansonius J. N. 1998Three-dimensional structure of O-acetylserine sulfhydrolase from
Carsten F. Christph S. Barbara H. et al. 2000Bcl-2 expression in high-grade human glioma: Clinical and exprimental study. J. Neurooncol. 48 207 216.
Casasnovas R. Salva A. Frau J. Donoso J. Munoz F. 2009Therotical study on the distribution of atomic charges in the Schiff base of 3-hydroxypyridine-4-aldehyde and alanine. The effect of the protonation state of the pyridine and imine nitrogen atoms. Chemical Physics. 355 149 156.
Cellarier E. Durando X. Vasson M. P. Farges M. C. Demiden A. Maurizis J. C. Madelmont J. C. Chollet P. 2003Methionine dependency and cancer treatment. Cancer Treat Rev 29 489 499
Cheng P. N. Leung Y. C. Lo W. H. Tsui S. M. Lam K. C. 2005Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to trans-heptic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett. 224 67 80.
Chin H.W. and Lindsay R.C. 1994Ascorbate and transition-metal mediation of methanethiol oxidation to dimethyldisulfide and dimethyltrisulfide. Food Chem. 49 387 392..
Choi S.W. and Mason J.B. 2002Folate status: effects on pathways of colorectal carcinogenesis: J. Nut. 132 2413 2418
Choi J. D. Bowers-Komoro M. Davis D. M. Edmondson D. E. Mc Cormick D. B. 1983Kinetic properties of pyridoxamine (pyridoxine)-5-phosphate oxidase from rabbit liver. J. Biol. Chem. 258 840 845.
Coffino P. 2000Polyamines in spermigenesis: Not now, darling. Proc. Natl. Acad Sci. USA. 97 4421 4423.
Coombs G.H. and Mottram J.C. 2001Trifluoromethionine, a prodrug designed against methionine gamma-lyase-containing pathogens, has efficacy
Cooper A.J.L. 1983Biochemistry of sulfur-containing amino acids. Annual Rev. Biochem 52 187 222
Davidson N. E. Hahm H. A. Mc Closkey D. E. Woster P. M. Casero Jr R. A. 1999Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr. Relat. Cancer 6 69 73.
Davis C.D. and Uthus E.O. 2004DNA methylation, cancer susceptibility and nutrient interactions. Exp. Biol. Med. 229 988 995.
De Bree A. Verscuren W. M. Kromhout D. Kluijtmans L. A. Blom H. J. 2002Homocysteine determinates and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol. Rev. 54 599 618.
Denesyuk A. I. Denessiouk K. A. Korpela T. Johnson M. S. 2002Functional attributes of the phosphate group binding cup of pyridoxal phosphate-dependent enzymes. J. Mol. Biol. 316 155 172.
Denesyuk A. I. Denessiouk K. A. Korpela T. Johnson M. S. 2003Phosphate group binding cup of PLP-dependent and non-PLP-dependent enzymes: Leitmotif and variations. Biochimica et Biophysica Acta, 1647 234 238.
Dominy J.E. and Stipanuk M.H. 2004New roles for cysteine and transsulfuration enzymes: production of H2S, a neuromodulator and smooth muscle relaxant. Nutr. Rev., 62 348 53.
Ehrenshaft M. Daub M. E. 2001Isolation of PDX2, a second novel gene in the pyridoxine biosynthesis pathway of eukaryotes, archaebacteria, and a subset of eubacteria. J. Bacterial. 183 3383 3390.
El-Sayed A.S.A. 2009L-Methioninase production by
El-Sayed A.S.A. 2010Microbial L-Methioninase, molecular characterization, and therapeutic applications. Appl. Microbiol. Biotechnol. 86 445 467.
El-Sayed A.S.A. 2011Purification and characterization of new L-methioninase from solid cultures of
El-Sayed A.S.A. and Shindia A.A. 2011Characterization and immobilization of purified
El -Sayed A. S. A. Fujimoto S. Yamada C. Suzuki H. 2010Enzymatic synthesis of γ-glutamylglutamine, a stable glutamine analogue, by γ-glutamyl-traspeptidase from
Fee C.J.and Van Alsteine J.M. 2004Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug. Chem. 15 1304 1313.
Finegold S.M. and Wexler H.M. 1996Present studies of therapy for anaerobic infections. Clinic. Infect. Dis. 23: S 9-S14.
Fiskerstrand T. Christensen B. Tysnes O. B. Ueland P. M. Refusm H. 1994Development and reversion of methionine dependence in a human glioma cell line: relation to homocysteine remethylation and cobalamin status. Cancer Res. 54 4899 4906.
Fox J.L. 1999Gene Therapy safety issues come to fore. Nature Biotechnology 17: 1153 EOF
Gadalla M.M. and Snyder S.H. 2010Hydrogen sulfide as a gasotransmitter. J. Neurochem. 113 14 26.
Gallagher D. T. Gilliland G. L. Xiao G. Zondlo J. Fisher K. Chinchilla D. Eisenstein E. 1998Structure and control of pyridoxal phosphate dependent allosteric threonine deaminase. Structure 6 465 475.
Galperin M.Y. and Koonin E.V. 1997Sequence analysis of an exceptionally conserved operon suggests enzymes for a new link between Histidine and purine biosynthesis. Mol. Micrbiol. 24 443 445.
Gerner E. W. Meyskens Jr F. L. 2004Polyamines and cancer: Old molecules, new understanding. Nature Rev. Cancer 4 781 792.
Gilmour S.K. 2007Polyamines and nonmelanoma skin cancer. Toxicol. Appl. Pharmacol. 224 249 256.
Goseki N. Yamazaki S. Endo M. Onodera T. Kosaki G. Hibino Y. Kuwahata T. 1992Antitumor effect of methionine-depleting total parenteral nutrition with doxorubicin administration on Yoshida sarcoma-bearing rats. Cancer 69 1865 1872.
Green D.R., and Reed J.C. 1998Mitochondria and apoptosis. Science 281 1309 1312.
Grishin N.V., Phillips M.A. and Goldsmith E.J. 1995Modeling of the spatial structure of eukaryotic ornithine decarboxylase. Protein Sci. 4 1291 1304.
Guo H. Lishko V. K. Herrera H. Groce A. Kubota T. Hoffman R. M. 1993Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res. 53 5676 5679.
Guo H. Tan Y. Kubota T. Moossa A. R. Hoffman R. M. 1996Methionine depletion modulates the antitumor and antimetastatic efficiency of ethionine. Anticancer Res., 16 2719 2723.
Gupta A. Miki K. Xu M. Yamamoto N. Mossa A. R. Hoffman R. M. 2003Combination efficiency of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res. 23 1181 1188
Hamel W. Magnelli L. Chiarugi V. P. Israel M. A. 1996Herpes simplex virus thymidine kinase/ ganciclovir-mediated apoptosis death of bystander cells. Cancer Res. 56 2697 2702.
Hansen J. Muldbjerg M. Cherest H. Surdin-Kerjan Y. 1997Siroheme biosynthesis in
Harris J. M. Martin N. E. Modi M. 2001PEGylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinetic. 40 539 551.
Harris M.J. 1991Poly (Ethylene glycol) Chemistry: Biotechnical and biomedical Applications. Plenum Press, New York.
Herschler R.J.U.S. 1962Patent 3,023, 074, Feb. 27.
Heyl D. L. Harris E. Folkers K. 1951Phosphates of vitamin B6 group I. The structure of Co-decarboxylase. J. American Chemical Society. 73 3430 3433.
Hirota M. Miyazaki S. Minakuchi T. Takagi T. Shibata H. 2002Myrsinoic acids B, C and F, anti-inflammatory compounds from
Hoet P. H. Nemery B. 2000Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Cell Mol. Physiol. 278 417 433.
Hoffman R.M. 1985Altered methionine metabolism and transmethylatin in cancer. Anticancer Res. 5 1 30
Hoffman R.M. 1984Altered methionine metabolism, DNA methylation, and oncogene expression in carcinogenesis: A review and synthesis. Biochem. Biophys Acta 738 49 87.
Hoffman R.M. and Erbe R.W. 1976High in vivo rate of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc. Natl. Acad.Sci. USA 73 1523 1527.
Hoshiya Y. Kubota T. Inada T. Kitajima M. Hoffman R. M. 1997Methionine-depletion modulates the efficiency of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res. 17 4371 4375.
Hu J. Cheung N. K. 2009Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. Int. J. Cancer. 124 1700 1706.
Hult K. Berglund P. 2007Enzyme Promiscuity: Mechanism and applications. TRENDS in Biotechnol. 25 231 238.
Hyde C. C. Ahmed S. A. Padlan E. A. Miles E. W. davis D. R. 1988Three-dimensional structure of the tryptophan synthase alpha 2 bet 2 multi-enzyme complex from
Igarashi K. Sakamoto I. Goto N. Kashiwangi K. Honma R. Hirose S. 1982Interaction between polyamines and nucleic acids or phospholipids. Arch. Biochem. Biophys. 219 438 443.
Ito S. Narise A. Shimura S. 2008Identification of a methioninase inhibitor, myrsinoic acid B, from
Izzo F. Montella A. P. Orlando A. P. Nasti G. Beneduca G. Castello G. 2007PEGylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J. Gastroenterol. Hepatol. 22 86 91.
Jansonius J.N. 1998Structure, evolution and action of vitamin B6-dependent enzymes. Current Opinion Structure Biol. 8 759 769.
Jin B. Ding S. Kametani K. Nakamura T. 2005The preparation and electrochemical behavior of density-controlled gold nano-particles self assembled interface. Chem Lett 34 302 303.
John R.A. 1995Pyridoxal phosphate-dependent enzymes. Biochim. Biophys Acta. 1248 81 96.
Johnson L. N. Acharya K. R. Jorrdan M. D. Mc Laughlin P. J. 1990Refined Crystals structure of the phosphorylase-heptulose 2-phosphate oligosaccharide-AMP complex. J. Mol. Biol. 211 645 661.
Johnston M. Jankowski D. Marcotte P. Tanaka H. Esaki N. Soda K. Walsh C. 1979Suicide inactivation of bacterial cystathionine γ-synthetase and methionine γ-lyase during processing of L-propargylglycine. Biochemistry 18 4690 4701.
Jones P.A. and Baylin S.B. 2002The fundamental role of epigenetic events in cancer. Nat Rev Genetic 3 415 428.
Kenyon S. H. Waterfield C. J. Timbrell J. A. Nicolaou A. 2002Methionine synthase activity and sulphur amino acid levels in the rat liver tumor cells HTC and Phi-1. Biochem Pharmacol. 63 381 391.
Kern A. D. Oliveira M. A. Coffino P. Hackert M. L. 1999Structure of mammalian ornithine deacrboxylase at 1.6°A resolution: Sterochemical implications of PLP-dependent amino acid decarboxylase. Structure 7 567 581.
Kessler D. 2006Enzymatic activation of sulfur for incorporation into biomolecules in prokaryotes. FEMS Microbiol. Rev. 30 825 840.
Kimura H. 2010Hydrogen sulfide: from brain to gut. Antioxid. Redox Sigal. 12 1111 1123.
Klimberg V.S. and McClellan J.L. 1996Glutamine, Cancer and its therapy. Am. J. Surg. 172 418 424.
Khalaf S.A. and El-Sayed A.S.A. 2009L-Methioninase production by filamentous fungi: I-Screening and optimization under submerged conditions. Curr. Microbiol. 58 219 226.
Kokkinakis D.M. 2006Methionine-stress: a pleiotropic approach in enhancing the efficacy of chemotherapy. Cancer Lett. 233 195 207.
Kokkinakis D. M. Hoffman R. M. Frenkel E. P. Wick J. B. Han Q. Xu M. Tan Y. Schold S. C. 2001Synergy between xenografts in athymic mice. Cancer Res. 61 4017 4023.
Kreis W. Goodenow M. 1978Methionine requirement ad replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells. Cancer Res 38 2259 2260.
Kudou D. Misaki S. Yamashita M. Tamura T. Takakura T. Yoshioka T. Yagi S. Hoffman R. M. Takimoto A. Esaki N. Inagaki K. 2007Structure of the antitumor enzyme L-methionine γ-lyase from
Kusakabe H. Kodama K. Machida H. Midorikawa Y. Kuninaka A. Misono H. Soda K. 1979Occurrence of a novel enzyme, L-lysine oxidase with antitumor activity in culture extract of
Le Magueres P. Im H. Ebalunode J. Strych U. Benedik M. J. Briggs J. M. Hohn H. Krause K. L. 2005The 1.9 Å crystal structure of alanine racemase from
Lishko V.K., Lishko O.V. and Hoffman R.M. 1993The preparation of endotoxin-free L-methionine-α-deamino-γ-mercaptomethane-lyase (L-Methioninase) from
Liteplo R. G. Hipwell S. E. Rosenblatt D. S. Sillaots S. Lue-Shing H. 1991Changes in cobalamine metabolism are associated with the altered methionine auxotrophy of highly growth autonomous human melanoma cells. J. Cell Physiol. 149 332 338.
Lockwood B. Coombs G. 1991Purification and Characterization of methionine γ-lyase from
Lopez C. Rios S. D. Lopez-Santin J. Caminal G. Alvaro G. 2010Immobilization of PLP-dependent enzymes with cofactor retention and enhanced stability. Biochem. Engin. J. 49 414 421.
Luka Z. Capdevila A. Mato J. M. Wagner C. 2006A glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme. Transgenic Res. 15 393 397.
Martinez-Lopez N. Varela-Rey M. Ariz U. Embade N. Vazquez-Chantada M. Fernandez-Ramos D. Gomez-Santos L. Lut S. C. Mato J. M. Martinez-Chantar M. L. 2008S-adenosylmethionine and proliferation: new pathways, new targets. Biochem. Soci. Trans. 63 848 852.
Matsukura S. Soejima H. Nakagawachi T. Yakushiji H. Ogawa A. Fukuhara M. Miyazaki K. Nakabeppu Y. Sekiguchi M. Mukai T. 2003CpG methylation of MGMT and hMLH1 promotor in hepatocellular carcinoma associated with hepatitis viral infection. British J. Cancer 88 521 529.
Mecham J. O. Rowitch D. Wallace C. D. Stern P. H. Hoffman R. M. 1983The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem. Biophys Res. Comm. 117 429 434.
Metha P. K. Christen P. 2000The molecular evolution of pyridoxal 5’-phosphate-dependent enzymes. Adv. Enzymol. 74 129 184.
Miki K. Al-Refaie W. Xu M. Jiang P. Tan Y. Bouvet M. Zhao M. Gupta A. Chishima T. Shimada H. Makuuchi M. Mossa A. R. Hoffman R. M. 2000aMethioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Cancer Res. 60 2696 2702.
Miki K. Xu M. An Z. Wang X. Yang M. Al-Refaie W. Sun X. Baranov E. Tan Y. Chishima T. Shimada H. Mossa A. R. Hoffman R. M. 2000bSurvival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model. Cancer Gene Therp. 2 332 338.
Miki K. Xu M. Gupta A. Ba Y. Tan Y. Al-Refaie W. Bouvet M. Makuuchi M. Mossa A. R. Hoffman R. M. 2001Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 61 6805 6810.
Morris M.S. 2003Homocysteine and Alzheimerʼs disease. Lancet. Neurol. 2 425 428.
Moruzzi M. S. Marverti G. Piccini G. Frassineti C. Monti M. G. 1993Effect of spermine on membrane-associated and membrane-inserted forms of protein kinase C. Mol. Cell Biochem. 124 1 9.
Motoshima H. Inagaki K. kumasaka T. Furuichi M. Inoue H. Tamura T. Esaki N. Soda K. Tanaka N. Yamamoto M. Tanaka H. 2000Crystal structure of the pyridoxal 5΄-phosphate dependent L-methioninase γ-lyase from
Mudd S. H. Skovby F. Levy H. L. Pettigerw K. D. Wilcken B. Pyeritz R. E. Andria G. Boers G. H. J. Bromberg I. L. Cerone R. Fowler B. grobe H. Schimidt H. Schweitzer L. 1985The natural history of homocysteinuria due to cystathionine β-synthase deficiency. Am. J. Hum. Genet. 37 1 31.
Nagahama T. goeski N. Endo M. 1998Doxorubicin and vincristine with methionine depletion contributed to survival in the Yoshida sarcoma bearing rats. Anticancer Res. 18 25 31.
Nakai T. Mizutani H. Miyahara I. Hirotsu K. Takeda S. Jhee K. H. 2000Three-dimensional structure of 4-amino-4-deoxychorismate lyase from
Nakamura T. Ren J. Zhu-M K. Kawara S. Jin B. 2006Application of the nanogold-4, 4′-bis (methanethiol) biphenyl modified gold electrode to the determina-tion of tyrosinase-catechol reaction kinetics in acetonitrile. Anal. Sci. 22 1261 1264.
Nakayama T. Esaki N. Lee-J W. Tanaka I. Tanaka H. Soda K. 1984Purification and properties of L-Methioninase γ-lyase from
Napier M. P. Sharma S. K. Springer C. J. Bagshawe K. D. Green A. J. Martin J. Stribbling S. M. Cushen N. O̕ Malley. D. Begent R. H. J. 2000Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clinical Cancer Res. 6 765 772.
Nikulin A. Revtovich S. Morozova E. Neveskaya N. Nikonov S. Garber M. Demidkina T. 2008High resolution structure of methionine γ-lyase from
Nitenberg G. Raynard B. 2000Nutritional support of the cancer patient: issues and dilemmas. Critical Rev. Oncology Hematology, 34 137 168.
O’Brien T.G. 1976The induction of ornithine decarboxylase over expression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 57 2630 2637.
Okada K. Hirotsu K. Sato M. Hayashi H. Kagamiyama H. 1997Three-dimensional structure of
Palm D. Klein H. W. Schinzel R. Buehner M. Helmreich E. J. M. 1990The role of pyridoxal-5-phosphate in glycogene phosphorylase catalysis. Biochemistry 29 1099 1107.
Pasut G. Veronese F. M. 2009PEG-Conjugates in clinical development or use as anticancer agents: An overview. Advan Drug Delivery Reviews 61 1177 1188.
Pasut G. Sergi M. Veronese F. M. 2007Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Advanced Drug Delivary Reviews
Pegg A.E. 1988Polyamine metabolism and its importance in neoplastic growth as a target for chemotherapy. Cancer Res. 48 759 774.
Percudani R. Peracchi A. 2003Agenomic overview of pyridoxal-phosphate dependent enzymes. EMBO Reports 4 850 854.
Persson L. Wallstrom E. L. Nasizadeh S. 1998Regulation of mammalian ornithine decarboxylase. Biochem. Soc. Tran. 26 575 579.
Poirson-Bichat F. Lopez R. Bras Goncalves. R. A. Miccoli L. Bourgeois Y. Demerseman P. Poisson M. Dutrillaux B. Poupon M. F. 1997Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas. Life Sci. 60 919 931.
Poirson-Bichat F. Bras Goncalves. R. A. Miccoli L. Dutrillaux B. Poupon M. F. 2000Methionine Depletion Enhances the Antitumoral Efficacy of cytotoxic agents in Drug-resistant Human Tumor Xenografts. Clinical Cancer Research 6 643 653.
Predmore B.L. and Lefer D.J. 2010Development of hydrogen sulfide-based therapeutics for cardiovascular disease. J. Cardiovascular Transl. Res. 3 487 498.
Pullon D.H.H. 1980Homocystinuria and other methioninemias, in neonatal screening for inborn errors of metabolism, edited by Bickel H, Guthrie R, hammersen G, New York, Springer-Verlag, 29 44.
Razin A. Riggs A. D. 1980DNA methylation and gene function. Science (Washington DC), 210 604 610.
Reddy K.R. 2000Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34 915.
Richard J.P. and Amyes T.L. 2004On the importance of being zwitterionic: enzymic catalysis of decarboxylation and deprotonation of cationic carbon. Bioorg. Chem. 32 354 366.
Saha B. Mukherjee S. Das A. K. 2009Molecular characterization of
Santini V. Kantarjian H. Issa J. P. 2001Changes in DNA methylation in neoplasia: Patho-physiology and therapeutic implications. Annual Intern. Med. 134 573 586.
Sato D. Yamagata W. Harada S. Nozaki T. 2008Kinetic characterization of methionine γ-lyase from the enteric protozoan parasite
Sato D. Nozaki T. 2009Methionine gamma-lyase: the unique reaction mechanism, physiological roles, and therapeutic applications against infectious disease and cancers. IUBMB Life 61 1019 1028.
Schirch D. Fratte D. Lurescia S. Iurescia S. Angelaccia S. Contestabile R. Bossa F. Schirch V. 1993Function of the active site lysine in
Schuh S., Rosenblatt D.S. and Cooper B.A. 1984Homocysteinuria and megaloblastic anemia responsive to vitamin B12 therapy. N. Eng. J. Med. 310 686 690.
Scott C.B., Dorsey W.S. and Huffman H.C. 1955Methyl mercaptan from methyl chloride. Industr. Engin. Chem. 47 876 877.
Sharma S.K., Begshawe K.D. and Begent R.H.J. 2005Advances in antibody-directed enzyme prodrug therapy. Current Opin. Investig. Drugs 6 611 615.
Shaw J. P. Petsko G. H. et al. 2000Determination of the structure of alanine racemase from
Soda A. Tanaka H. Esaki N. 1983Multifunctional biocatalysis: methionine-γ-lyase. Trends Biochem. Sci. 8 214 217.
Sprang S. Fletterick R. J. 1979The structure of glycogen phosphorylase alpha at 2.5°A resolution. J. Mol. Bio. 131 523 551
Stener P.D. and Springer C.J. 2001Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug. Deliv. 53 247 264.
Stern P.H., Wallace C.D. and Hoffman R.M. 1984Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J. Cell Phys. 119 29 34.
Stewart RA, Lasis 1965(1965) US. Patent 3,196,143, July 20, 1965
Stipanuk M.H. 2004Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Ann. Rev. Nutr. 24 539 577.
Sugio S. Petsko G. A. Manning J. M. Soda D. 1995Crystal structure of a D-amino acid aminotransferase: How the protein controls stereoselectivity. Biochemistry, 34 9661 9669.
Sun X. Yang Z. Li S. Tan Y. Zhang N. Wang X. Yagi S. Yoshioka T. Takimoto A. Mitsushima K. Suginaka A. Frankel E. P. Hoffman R. M. 2003In vivo efficiency of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5-phosphate supplementation. Cancer Res. 63 8377 8383.
Sun L. Hui A. M. Kanai Y. Sakamoto M. Hirohashi S. 1997Increased DNA methyltransferase expression is associated with an early stage of human hepato-carcinogenesis. Jpn. J. Cancer Res. 88 1165 1170.
Swisher E. M. Gonzalez R. M. Taniguchi T. Garcia R. L. Wash T. Goff B. A. Welcsh P. 2009Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8 1 11
Tan Y. Sun X. Xu M. An Z. Tan X. Tan X. Han Q. Miljkovic D. A. Yang M. Hoffaman R. M. 1998: Polyethylene glycol conjugation of Recombinant methioninase for cancer therapy. Protein Expr. Purif. 12 45 52.
Tan Y. Xu M. Guo H. Sun X. Kubota T. Hoffman R. M. 1996Anticancer efficiency of methioninase in vivo. Anticancer Res. 16 3931 3936
Tanaka H. Esaki N. Soda K. 1977Properties of L-methionine γ-lyase from
Thomas D. Barbey R. Surdin-Kerjan Y. 1997Gene enzyme relationship in the sulfate assimilation pathway of
Thornton J. M. Todd A. E. Milburn D. Borkakoti N. Orengo C. A. 2000From structure to function: approaches and limitations. Nature Struct. Biol. 7 991 994.
Toney M.D. 2005reaction specificity in pyridoxal phosphate enzymes. Arch. Biochem. Biophys 433 279 287.
and Lucocq J.M. Tover J. Leon-Avila G. Sachez L. B. Sutak R. Tachezy J. Van der Giezen M. Hernadez M. Muller 2003Mitochondrial remnant organelles of Giardia function in iron-sulphur protein maturation. Nature 426 172 176.
Vellard M. 2003The enzyme as drug: application of enzymes as pharmaceuticals. Curr. Opin Biotechnol. 14 444 450.
Veronese F.M. and Harris J.M. 2002Theme issue on peptide and protein PEGylation I. Adv. Drug Deliv. Rev. 54 453 609.
Veronese F. M. Pasut G. 2005PEGylation, successful approach to drug delivery. Drug Discovery Today 21 1451 1458.
Wald D. S. Law M. Morris J. K. 2002Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 1202 1206.
Wang J. Hegele R. A. 2003Genomic basis of cystahioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma lyase (CTH). Human Genetic 112 404 408.
Wang R. 2002Twoʼs Company, threeʼs a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J. 16 1792 1798.
Watson K. A. Mc Cleverty C. Germia S. Cottaz S. Driguez H. Johnson L. N. 1999Phosphorylase recognition and phosphorolysis of its oligosaccharide substrate: Answers to a long outstanding question. EMBO J. 18 4619 4632.
Welirnan H.B. 1966U. S. Patent 3, 236, 046, Feb. 22.
Yamamoto N. Gupta A. Xu M. Miki K. Tsugimoto Y. Tsuchiya H. Tomita K. Mossa A. R. Hoffman A. R. 2003Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Therp. 10 445 450.
Yang Z. Wang J. Yoshioka T. Li B. Lu Q. Li S. Sun X. Tan Y. Yagi S. Frankel E. P. Hoffman R. M. 2004Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clinical Cancer Res. 10 2131 2138.
Yang-Q Y. Yuan-Z Y. Dai-J S. Wang B. Zhang-B H. 1998The catalytic properties of supported K2MoS4/SiO2 catalyst for methanethiol synthesis from high H2S-content syngas. Catalysis Lett. 54 65 68.
Yoshimura M. Nakano Y. Koga T. 2002L-Methionine-gamma-lyase, as a target to inhibit malodorous bacterial growth by trifluoromethionine. Biochem. Biophys. Res. Commun. 292 964 968.
Yoshioka T. Wada T. Uchida N. Maki H. Yoshida H. Ide N. Kasai H. Hojo K. Shono K. Maekawa R. Yagi S. Hoffman R. M. Sugita K. 1998Anticancer efficiency in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res. 58 2583 2587.
Zalipsky S. 1995Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. 6 150 165.
Zhao R. Domann F. E. Zhong W. 2006Apoptosis induced by selenomethionine and methioninase is superoxide-mediated and 53in human prostate cancer cells. Mol. Cancer Therp. 5: 3275-3284.
Zhu W. Lin A. Banerjee R. 2008Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine γ-lyase. Biochemistry 47 6226 6232.
Zou C. G. Banerjee R. 2005Homocysteine and redox signaling. Antioxidant Redox Sig. 7 547 559.
Zygmunt W.A. and Tavormina P.A. 1966Dl-S-Trifluoromethyl-homocysteine, a novel inhibitor of microbial growth. Can. J. Microbiol. 12 143 148.